Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines
详细信息 查看全文
- 作者：Zhengyun Zou (1)
Li Xie (1)
Jia Wei (1)
Lixia Yu (1)
Xiaoping Qian (1)
Junhao Chen (2)
Tingting Wang (3)
Baorui Liu (1) - 刊名：BMC Complementary and Alternative Medicine
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：12
- 期：1
- 全文大小：1200KB
- 参考文献：1. Crew KD, Neugut AI: Epidemiology of gastric cancer. / World J Gastroenterol 2006,12(3):354鈥?62.
2. Parkin DM, / et al.: Global cancer statistics, 2002. / CA Cancer J Clin 2005,55(2):74鈥?08. lin.55.2.74">CrossRef
3. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. / J Clin Oncol 2006,24(14):2137鈥?150. CrossRef
4. Janunger KG, Hafstrom L, Glimelius B: Chemotherapy in gastric cancer: a review and updated meta-analysis. / Eur J Surg 2002,168(11):597鈥?08. CrossRef
5. Ocvirk J, / et al.: Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. / World J Gastroenterol 2010,16(25):3133鈥?143. CrossRef
6. Bokemeyer C, / et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. / J Clin Oncol 2009,27(5):663鈥?71. CrossRef
7. Trudeau ME: Docetaxel: a review of its pharmacology and clinical activity. / Can J Oncol 1996,6(1):443鈥?57.
8. Mavroudis D, / et al.: Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. / Am J Clin Oncol 2000,23(4):341鈥?44.
9. Einzig AI, / et al.: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. / Med Oncol 1996,13(2):87鈥?3. CrossRef
10. Ridwelski K, / et al.: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. / Ann Oncol 2001,12(1):47鈥?1. CrossRef
11. Wang T, / et al.: Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. / Cancer Lett 2008,262(2):214鈥?22. CrossRef
12. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. / Adv Enzyme Regul 1984, 22:27鈥?5. CrossRef
13. Bhat KM, Setaluri V: Microtubule-associated proteins as targets in cancer chemotherapy. / Clin Cancer Res 2007,13(10):2849鈥?854. CrossRef
14. Johnson ME, Howerth EW: Survivin: a bifunctional inhibitor of apoptosis protein. / Vet Pathol 2004,41(6):599鈥?07. CrossRef
15. Woll E, / et al.: Chemotherapy in gastric cancer. / Anticancer Res 2008,28(2):1213鈥?219.
16. Goyle S, Maraveyas A: Chemotherapy for colorectal cancer. / Dig Surg 2005,22(6):401鈥?14. CrossRef
17. Sastre J, Garcia-Saenz JA, Diaz-Rubio E: Chemotherapy for gastric cancer. / World J Gastroenterol 2006,12(2):204鈥?13.
18. Alisi A, Balsano C: Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents. / Nutr Rev 2007,65(12 Pt 1):550鈥?53. CrossRef
19. Geney R, Chen J, Ojima I: Recent advances in the new generation taxane anticancer agents. / Med Chem 2005,1(2):125鈥?39.
20. Guo QL, / et al.: Gambogic acid inducing apoptosis in human gastric adenocarcinom SGC-7901 cells. / Chin J Nat Med 2004, 2:107鈥?10.
21. Liu W, / et al.: Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. / World J Gastroenterol 2005,11(24):3655鈥?659.
22. Wang J, / et al.: Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. / Toxicology 2009,256(1鈥?):135鈥?40. CrossRef
23. Kawasaki H, / et al.: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. / Cancer 2001,91(11):2026鈥?032. CrossRef
24. Zaffaroni N, Daidone MG: Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. / Drug Resist Updat 2002,5(2):65鈥?2. CrossRef
25. Urano N, / et al.: Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. / Int J Oncol 2006,28(2):375鈥?81.
26. Rouzier R, / et al.: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. / Proc Natl Acad Sci U S A 2005,102(23):8315鈥?320. CrossRef
27. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/58/prepub - 作者单位：Zhengyun Zou (1)
Li Xie (1)
Jia Wei (1)
Lixia Yu (1)
Xiaoping Qian (1)
Junhao Chen (2)
Tingting Wang (3)
Baorui Liu (1)
1. The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, 210008, China
2. Department of Laboratory, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China
3. Medical School of Nanjing University, Nanjing, 210008, China
文摘